Industry veteran brings 30 years of commercial leadership experience
Lifeward Ltd, a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced that Mark Grant has been appointed as the Company’s new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward’s outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025.
Health Technology Insights: Viventium Partners with Exclugo to Transform Healthcare Exclusion Monitoring
“Mark brings 30 years of combined experience in commercial leadership, channel development and strategic solutions, and is the perfect choice to lead Lifeward in its next stage of growth,” said Joseph Turk, Chairman of the Lifeward Board of Directors. “As a leader, Mark has managed teams in multiple geographies and has led critical functions, including Americas field and inside sales, field clinicians, managed markets, sales channels, health economics and reimbursement, sales training and enablement, revenue cycle management, marketing, and global customer service.
“I want to welcome Mark on behalf of the entire Lifeward Board; we look forward to working with him to help drive innovations that change the lives of individuals with physical limitations, impairments, or disabilities, including spinal cord injuries. I also want to thank Larry for his unwavering commitment to Lifeward over the years, and for his valued support in facilitating a seamless leadership transition.”
“I’m thrilled and honored to be joining the Lifeward team at such an exciting time in its history,” said Mr. Grant. “In the last year, the Company has taken great strides, including the major milestone of achieving Medicare payment for the ReWalk exoskeleton while building a robust pipeline of ReWalk cases.
“ReWalk is representative of Lifeward’s robust portfolio of life-changing, breakthrough solutions, which are based on the Company’s wealth of technical expertise, R&D capabilities, and patented robotics technology. As CEO, I look forward to helping Lifeward leverage its many strengths to achieve balanced and sustainable growth as we establish a strong foundation for the future and work strategically toward profitability.
“Furthermore, I look forward to working with our valued partners in the patient advocacy community who share Lifeward’s profound commitment to improving the quality of life of the patients we have the honor of serving.”
Health Technology Insights: Datavant Acquires Aetion to Boost Real-World Evidence
From 2004 to 2023, Mr. Grant held various leadership roles at Medtronic, a global leader in healthcare technology, rising to the level of Vice President for the Americas. His responsibilities and achievements included directing the development and execution of strategies to deliver annual revenue targets in the highly competitive diabetic home care market, opening commercial markets by establishing access to new direct-payer constituencies, including the U.S. Department of Veterans Affairs, optimizing revenue cycle operations, identifying and pursuing new business opportunities based on market trends and competitor research, and restructuring the business to meet changing operational demands.
Prior to joining Lifeward, Mr. Grant was President of Americas and Chief Commercial Officer of IMRA Surgical, a global leader in ethical surgical training solutions. While there, he provided executive leadership in setting operational and commercial strategies to establish infrastructure for a new category of ethical surgical procedures through novel material science. He also spearheaded the development of multi-channel sales and marketing efforts to bolster commercialization efforts and played an integral leadership role in raising capital and developing the company’s enterprise strategy.
Prior to joining Medtronic, Mr. Grant had roles at Bristol Myers Squibb and FLA Orthopedics. He has a Bachelor of Science degree in industrial technology from East Carolina University.
Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
In connection with the appointment of Mr. Grant, the Board of Directors of Lifeward approved an inducement award of 400,000 options to purchase ordinary shares of Lifeward as an inducement material to Mr. Grant’s entering into employment with Lifeward in accordance with Nasdaq Listing Rule 5635(c)(4), subject to the terms and conditions of the applicable award agreement covering such grant. The grant will be made on the date he joins the Company. The options will have an exercise price equal to the closing price of the Company’s ordinary shares on the Nasdaq Capital Market on the date of grant and will vest in four equal annual installments beginning on the first anniversary of the grant date, subject to Mr. Grant’s continued employment with the Company on such vesting dates.
Health Technology Insights: Haier Ranks Among Top Global Brands as Leading IoT Brand
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – GlobeNewswire
